Center of Neuroproteomics and Biomarker Research, Departments of Psychiatry, University of Florida, College of Medicine and McKnight Brain Institute, Gainesville, FL, USA.
Proteomics Clin Appl. 2008 Oct;2(10-11):1467-83. doi: 10.1002/prca.200800011. Epub 2008 Aug 26.
The rapidly growing field of neuroproteomics has expanded to track global proteomic changes underlying various neurological conditions such as traumatic brain injury (TBI), stroke, and Alzheimer's disease. TBI remains a major health problem with approximately 2 million incidents occurring annually in the United States, yet no affective treatment is available despite several clinical trials. The absence of brain injury diagnostic biomarkers was identified as a significant road-block to therapeutic development for brain injury. Recently, the field of neuroproteomics has undertaken major advances in the area of neurotrauma research, where several candidate markers have been identified and are being evaluated for their efficacy as biological biomarkers in the field of TBI. One scope of this review is to evaluate the current status of TBI biomarker discovery using neuroproteomics techniques, and at what stage we are at in their clinical validation. In addition, we will discuss the need for strengthening the role of systems biology and its application to the field of neuroproteomics due to its integral role in establishing a comprehensive understanding of specific brain disorder and brain function in general. Finally, to achieve true clinical input of these neuroproteomic findings, these putative biomarkers should be validated using preclinical and clinical samples and linked to clinical diagnostic assays including ELISA or other high-throughput assays.
神经保护组学是一个快速发展的领域，其研究范围已经扩展到追踪各种神经状况（如创伤性脑损伤 (TBI)、中风和阿尔茨海默病）下的全球蛋白质组变化。TBI 仍然是一个主要的健康问题，在美国每年大约有 200 万例发生，但尽管进行了几次临床试验，仍没有有效的治疗方法。缺乏脑损伤诊断生物标志物被认为是脑损伤治疗发展的一个重大障碍。最近，神经保护组学领域在神经创伤研究领域取得了重大进展，已经确定了几个候选标志物，并正在评估它们作为 TBI 生物标志物的功效。本综述的一个目的是评估使用神经保护组学技术发现 TBI 生物标志物的现状，以及我们在其临床验证方面处于什么阶段。此外，我们还将讨论加强系统生物学作用及其在神经保护组学领域的应用的必要性，因为它在建立对特定脑疾病和脑功能的全面理解方面起着不可或缺的作用。最后，为了实现这些神经保护组学发现的真正临床应用，应该使用临床前和临床样本对这些假定的生物标志物进行验证，并将其与包括 ELISA 或其他高通量检测在内的临床诊断检测相关联。
